- SynonymVSIG4,CRIg,Z39IG
- SourceHuman VSIG4, His Tag (VS4-H5226) is expressed from human 293 cells (HEK293). It contains AA Arg 20 - Pro 283 (Accession # AAH10525).Predicted N-terminus: Arg 20Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 30.1 kDa. The protein migrates as 35-47 kDa under reducing (R) condition (SDS-PAGE).
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human VSIG4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
- BackgroundV-set and immunoglobulin domain-containing protein 4 (VSIG4) is also known as Protein Z39Ig, is a type Itransmembrane glycoprotein. VSIG4 is a B7 family-related protein and an Ig superfamily member. VSIG4 contains two Ig-like (immunoglobulin-like) domains. VSIG4 is abundantly expressed in several fetal tissues. In adult tissues, the highest expression of VSIG4 is in lung and placenta. VSIG4 functions as a negative regulator of T cell activation, and may be involved in the maintenance of peripheral T cell tolerance, and is also identified as a potent suppressor of established inflammation. VSIG4 is a phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production.
- References
- (1)Vogt L., et al., 2006, J. Clin. Invest. 116:2817-2826.
- (2)Wiesmann C., et al., 2006, Nature 444:217-220.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
